AU2014248164B2 - Pharmaceutical formulations for subcutaneous administration of furosemide - Google Patents

Pharmaceutical formulations for subcutaneous administration of furosemide Download PDF

Info

Publication number
AU2014248164B2
AU2014248164B2 AU2014248164A AU2014248164A AU2014248164B2 AU 2014248164 B2 AU2014248164 B2 AU 2014248164B2 AU 2014248164 A AU2014248164 A AU 2014248164A AU 2014248164 A AU2014248164 A AU 2014248164A AU 2014248164 B2 AU2014248164 B2 AU 2014248164B2
Authority
AU
Australia
Prior art keywords
furosemide
tris
pharmaceutical formulation
solution
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014248164A
Other languages
English (en)
Other versions
AU2014248164A1 (en
Inventor
Glenn R. Larson
Scott A. Michaels
Pieter Muntendam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ScPharmaceuticals Inc
Original Assignee
ScPharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ScPharmaceuticals Inc filed Critical ScPharmaceuticals Inc
Publication of AU2014248164A1 publication Critical patent/AU2014248164A1/en
Assigned to SCPHARMACEUTICALS, INC. reassignment SCPHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: SCPHARMACEUTICALS, LLC
Application granted granted Critical
Publication of AU2014248164B2 publication Critical patent/AU2014248164B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014248164A 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide Active AU2014248164B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
US61/808,962 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Publications (2)

Publication Number Publication Date
AU2014248164A1 AU2014248164A1 (en) 2015-10-15
AU2014248164B2 true AU2014248164B2 (en) 2019-05-23

Family

ID=51659206

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014248164A Active AU2014248164B2 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Country Status (14)

Country Link
US (5) US9884039B2 (enExample)
EP (3) EP2981258B8 (enExample)
JP (2) JP6415535B2 (enExample)
KR (2) KR102266460B1 (enExample)
CN (1) CN105431145B (enExample)
AU (1) AU2014248164B2 (enExample)
CA (1) CA2908935C (enExample)
DK (1) DK2981258T3 (enExample)
ES (1) ES2823589T3 (enExample)
IL (1) IL241917B (enExample)
MX (1) MX367165B (enExample)
PT (1) PT2981258T (enExample)
SG (2) SG11201508251RA (enExample)
WO (1) WO2014165660A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431145B (zh) * 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
DE102014115951A1 (de) * 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
IL300152A (en) * 2020-08-05 2023-03-01 Scpharmaceuticals Inc Methods of treatment using furosemide
WO2022212813A1 (en) 2021-04-02 2022-10-06 Scpharmaceuticals Inc. Subcutaneous infusion of furosemide
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814623A (en) * 1994-09-01 1998-09-29 Academic Pharmaceuticals, L.P. Parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamides
US20120077829A1 (en) * 2008-03-17 2012-03-29 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
ES2136090T3 (es) * 1991-05-30 1999-11-16 Abbott Lab Reactivos que contienen un inhibidor de fijacion no especifico para analisis de fijacion con captura de iones.
AU4866196A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
PL1803934T3 (pl) 2005-12-28 2009-03-31 Sensile Pat Ag Mikropompa
ES2780193T3 (es) * 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
MX340669B (es) * 2008-09-09 2016-07-20 Cima Labs Inc Formas farmaceuticas para compuestos debilmente ionizables.
MX2012002762A (es) * 2009-09-04 2012-06-12 Minipumps Llc Parche cutaneo adhesivo con bomba para suministro subcutaneo de farmacos.
CN103998047A (zh) 2011-10-19 2014-08-20 墨卡托医疗系统公司 局部调节组织和细胞以提高疗效包括肾去神经支配
CN105431145B (zh) 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12042709B1 (en) * 2022-02-22 2024-07-23 Craig E. Williams Fighting training device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814623A (en) * 1994-09-01 1998-09-29 Academic Pharmaceuticals, L.P. Parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamides
US20120077829A1 (en) * 2008-03-17 2012-03-29 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone

Also Published As

Publication number Publication date
US20160051507A1 (en) 2016-02-25
US20250339397A1 (en) 2025-11-06
JP2016515623A (ja) 2016-05-30
KR20210075211A (ko) 2021-06-22
EP3799869A1 (en) 2021-04-07
MX2015014064A (es) 2017-04-13
US20230201156A1 (en) 2023-06-29
EP2981258B1 (en) 2020-08-12
EP4696308A1 (en) 2026-02-18
ES2823589T3 (es) 2021-05-07
CN105431145B (zh) 2019-12-10
KR102493735B1 (ko) 2023-01-30
US10272064B2 (en) 2019-04-30
JP6415535B2 (ja) 2018-10-31
JP6677779B2 (ja) 2020-04-08
BR112015025204A2 (pt) 2021-03-16
US20180303790A1 (en) 2018-10-25
KR102266460B1 (ko) 2021-06-17
MX367165B (es) 2019-08-07
CN105431145A (zh) 2016-03-23
CA2908935C (en) 2021-06-15
US11433044B2 (en) 2022-09-06
US12370168B2 (en) 2025-07-29
HK1221152A1 (zh) 2017-05-26
SG10201709388QA (en) 2017-12-28
US20200038364A1 (en) 2020-02-06
CA2908935A1 (en) 2014-10-09
EP2981258A1 (en) 2016-02-10
KR20160014592A (ko) 2016-02-11
EP2981258A4 (en) 2016-10-05
DK2981258T3 (da) 2020-10-19
EP3799869B1 (en) 2025-08-27
EP2981258B8 (en) 2020-11-11
AU2014248164A1 (en) 2015-10-15
PT2981258T (pt) 2020-10-19
WO2014165660A1 (en) 2014-10-09
IL241917B (en) 2020-10-29
JP2019001821A (ja) 2019-01-10
US9884039B2 (en) 2018-02-06
SG11201508251RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
US12370168B2 (en) Pharmaceutical formulations for subcutaneous administration of furosemide
TWI674899B (zh) 醫藥配方
JP2018515484A (ja) カバジタキセル脂肪乳剤注射剤、その調製方法およびその使用
AU2020214314B2 (en) Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2018516989A (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
JP2018527358A (ja) 安定化されたグルカゴン溶液
US20260000636A1 (en) Pharmaceutical compositions of furosemide and uses thereof
US20230405018A1 (en) Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators
HK40049405A (en) Pharmaceutical formulations for subcutaneous administration of furosemide
HK40049405B (en) Pharmaceutical formulations for subcutaneous administration of furosemide
HK1221152B (en) Pharmaceutical formulations for subcutaneous administration of furosemide
BR112015025204B1 (pt) Formulação farmacêutica líquida de furosemida e seu uso
EA046008B1 (ru) Концентрированные жидкие фармацевтические составы фуросемида и способы их введения
CN118105338A (zh) 一种尼莫地平水溶性注射液及其制备方法
DE102007014947A1 (de) Stabilisierte wässrige Lösungen von Ergolinverbindungen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)